These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration. Inoue M; Yamane S; Sato S; Sakamaki K; Arakawa A; Kadonosono K Am J Ophthalmol; 2016 Sep; 169():95-103. PubMed ID: 27320059 [TBL] [Abstract][Full Text] [Related]
29. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Ng P; Pecheur FL; McAllister IL JAMA Ophthalmol; 2019 Apr; 137(4):372-379. PubMed ID: 30676617 [TBL] [Abstract][Full Text] [Related]
30. Vision-related quality of life in Japanese patients with wet age-related macular degeneration treated with intravitreal aflibercept in a real-world setting. Gomi F; Migita H; Sakaguchi T; Okada H; Sugawara T; Hikichi Y; Jpn J Ophthalmol; 2019 Nov; 63(6):437-447. PubMed ID: 31673841 [TBL] [Abstract][Full Text] [Related]
31. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy. Monés J; Biarnés M; Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111 [TBL] [Abstract][Full Text] [Related]
32. Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study. Ohji M; Okada AA; Sasaki K; Moon SC; Machewitz T; Takahashi K; Graefes Arch Clin Exp Ophthalmol; 2021 Dec; 259(12):3637-3647. PubMed ID: 34283294 [TBL] [Abstract][Full Text] [Related]
33. Intravitreal aflibercept for diabetic macular edema. Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934 [TBL] [Abstract][Full Text] [Related]
34. Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME). Korobelnik JF; Kleijnen J; Lang SH; Birnie R; Leadley RM; Misso K; Worthy G; Muston D; Do DV BMC Ophthalmol; 2015 May; 15():52. PubMed ID: 25975823 [TBL] [Abstract][Full Text] [Related]
36. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies. Steinle NC; Du W; Gibson A; Saroj N Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314 [TBL] [Abstract][Full Text] [Related]
37. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials. Waldstein SM; Simader C; Staurenghi G; Chong NV; Mitchell P; Jaffe GJ; Lu C; Katz TA; Schmidt-Erfurth U Ophthalmology; 2016 Jul; 123(7):1521-9. PubMed ID: 27157149 [TBL] [Abstract][Full Text] [Related]
38. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice. Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633 [TBL] [Abstract][Full Text] [Related]
39. A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis. Singh RP; Srivastava S; Ehlers JP; Bedi R; Schachat AP; Kaiser PK Br J Ophthalmol; 2014 Jun; 98 Suppl 1(Suppl 1):i22-27. PubMed ID: 24836866 [TBL] [Abstract][Full Text] [Related]
40. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY. Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]